Last reviewed · How we verify
Control product
Control product, marketed by Colgate Palmolive, holds a position in the consumer healthcare market with a key composition patent expiring in 2028. The primary strength of the product lies in its established market presence and brand recognition. The main risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Control product |
|---|---|
| Sponsor | Colgate Palmolive |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rosacea and Ivermectin (PHASE2)
- The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- The Impact of Equine-Assisted Therapy on Mental Health and Addictive Behaviors in Patients Receiving Addiction Treatment (NA)
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects (NA)
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control product CI brief — competitive landscape report
- Control product updates RSS · CI watch RSS
- Colgate Palmolive portfolio CI